

**CAPE TOWN INTERNATIONAL CONVENTION CENTRE, SOUTH AFRICA
3 – 8 DECEMBER 2016**

Seminar is open – please pre-register online to secure a seat

Saturday, 3 December 2016

HIV Drug Resistance Testing Workshop

08h00 – 17h00, Room 2.41 - 2.43

The interest in HIV drug resistance testing for surveillance, clinical management and research in resource-limited settings is increasing. This workshop will have a technical, clinical and surveillance component in order to target a wide audience.

The **principles of drug resistance** will be discussed followed by the technical component of HIV drug resistance testing, from **setting up a molecular laboratory** to the principles of **HIV drug resistance assays** and sequence analysis. Discussions will include the necessity of having specific laboratory workflow, required equipment, the application of good clinical laboratory practice in an HIV drug resistance laboratory and specific technologies such as Sanger sequencing and next generation sequencing. Finally, **sequencing data analysis, quality control, the use of drug resistance prediction algorithms** and the consequent interpretation of results will be presented.

The technical module will be followed by a clinical module, focusing on **local and international HIV drug resistance testing guidelines**, the clinical interpretation of HIV drug resistance results and some **case studies**.

Finally we will discuss what **HIV drug resistance** means at a **public health level**, present some of the survey findings in the region and how these results should be interpreted by health care workers.

Agenda

Introduction to HIV drug resistance	Dr K. Steegen
Laboratory aspects of HIVDR testing	Dr K. Steegen and Dr G. Hunt
Design and Implementation of HIV DR Testing Services in Kenya	Dr M. Mwau
Interpretation of sequencing data and basic QC	Dr K. Steegen and Dr G. Hunt
Troubleshooting of HIVDR assays	Dr K. Steegen and Dr G. Hunt
HIVDR testing and 3 rd -line ART committee in South Africa	Dr M. Moorhouse
Clinical interpretation of HIVDR	Dr M. Moorhouse and Dr J. Nuttal
Considerations of HIVDR at a public health level: Do we need to worry about HIVDR?	Dr S. Carmona and Dr G. Hunt